Search

LANGHORNE, Pa. -- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to four new employees. On November [...]

Acute Respiratory Diseases and Infections Reentered the National Top Five Telehealth Diagnostic Categories after Being outside the Top Five in July Telehealth Utilization Increased Nationally and in Every US Census [...]

LANGHORNE, Pa. -- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside [...]

SILVER SPRING, Md., Oct. 25, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA updated [...]

M2 PRESSWIRE-October 9, 2024-: End 'collective amnesia' over COVID-19, says UN health agency WHO (C)1994-2024 M2 COMMUNICATIONS RDATE:09102024 Our 'collective amnesia' about how bad the COVID-19 pandemic was should not [...]

Twenty-five U.S. health systems to implement PCORI-funded CER results on either antibiotic use or weight loss treatment WASHINGTON, Oct. 2, 2024 /PRNewswire/ -- The Patient-Centered Outcomes Research Institute (PCORI) today [...]

2024 OCT 20 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Data detailed on COVID-19 have been presented. According to news [...]

GSK plc has reported new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy and safety of a single dose of AREXVY (Respiratory Syncytial Virus [...]

LANGHORNE, Pa. -- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, will host an analyst and investor webinar on September 30, 2024 [...]

InBios International Inc., a leading developer of diagnostic tests for emerging infectious diseases, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its [...]

SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=7jDpv0iJHQOtRVK1G3PsBk4fjNWJubri2On3bIAyU6sJtpcNUmWbrX7gre_70u56N_zscocNickwoezMLqTHBRz-L_E0FdQf1sGs6zprGdo= reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired [...]

SAN DIEGO, Aug. 20, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=yjBW0XRZ6zWAqSNbnIdVfyA8Vb2Jk-6_Hv91mlEctBlnzU539iouHYF_4H3sbocer9gIR-5JspMTje8KVNIHCYXmvMyyW2jAfsxgKxoklVI= reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired [...]

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the 'Class') who purchased [...]

NEWTOWN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. ('Traws' or 'Traws Pharma'), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer, [...]

SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=z_MttOzNf9GmV6l-w4qlqS813APEN5hgm84HmyPdqCgAsD5t5pAWq7MGuH9-ohZmYK62CNCDVZeEzQUOER_lKpbD1YfOZTJlbrEdKzbXzOk= reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired [...]

2024 SEP 8 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Investigators publish new report on Respiratory Tract Diseases and Conditions [...]

2024 AUG 25 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Researchers detail new data in COVID-19. According to news reporting [...]

2024 AUG 11 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Current study results on COVID-19 have been published. According to [...]

2024 AUG 11 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Researchers detail new data in COVID-19. According to news originating [...]

2024 JUL 21 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Bioaerosols include bacteria, fungi, fungal spores and plant pollen, as [...]

LANGHORNE, Pa. -- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at [...]

AP01 (Inhaled Pirfenidone) Treatment Demonstrated Substantially Improved Efficacy and Tolerability Out to 3.5 Years Compared to Historical Data with Oral Pirfenidone Additional Poster Presentations Highlighted Post-hoc Analyses of the ATLAS [...]

The collaboration is underpinned by a shared commitment to advancing medical science and improving patient care through joint research, development, and innovation efforts One of the first areas of focus [...]

LANGHORNE, Pa. -- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at [...]

Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in [...]

CUMBERLAND, Md., April 30, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, announced [...]

EAGAN, Minn., April 9, 2024 /PRNewswire/ -- ABM Respiratory Care, a medical technology company focused on developing and globally commercializing novel airway clearance and ventilation solutions, is excited to announce [...]

Byline: Chrissy Booker Jan. 13With the onset of cold weather, respiratory illnesses are usually not far behind. According to Clark County Public Health, the respiratory disease season starts in October [...]

LANGHORNE, Pa. -- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at [...]

On 29 Feb 2024, Pfizer Inc announced top-line ABRYSVO vaccine efficacy and safety data for respiratory syncytial virus (RSV) in adults 60 years of age and older following a second season in the Northern and Southern Hemispheres from the ongoing pivotal Phase 3 clinical trial (NCT05035212) RSV vaccine Efficacy study iNOlder adults Immunized against RSV disease (RENOIR). Vaccine efficacy against RSV-associated lower respiratory tract disease (LRTD), defined by three or more symptoms, after disease surveillance in season two was 77.8% (95.0% CI: 51.4, 91.1); vaccine efficacy following season one was 88.9% (95.0% CI: 53.6%, 98.7%), which demonstrates durable efficacy after two seasons. Consistent vaccine efficacy was demonstrated for both RSV A and RSV B after season two with vaccine efficacy against each subtype of greater than or equal to 80% for LRTD with three or more symptoms. Vaccine efficacy was also sustained against less severe LRTD, defined by two or more symptoms, from 65.1% (95.0%% CI: 35.9%, 82.0%) after season one to 55.7% (95.0% CI: 34.7%, 70.4%) after the end of season two. Vaccine efficacy against RSV-associated LRTD, defined by three or more symptoms, across both seasons after approximately 16.4 months of disease surveillance was 81.5% (95.0% CI: 63.3, 91.6). No new adverse events were reported through the second RSV season beyond what was reported by subjects in the clinical trial during the first season. Pfizer is conducting post-marketing studies and surveillance programmes to inform the safety profile of ABRYSVO. Pfizer intends to submit these data to regulatory authorities and vaccine technical committees. The company also intends to publish these findings in a peer-reviewed scientific journal and share them at an upcoming scientific congress. Original source: Pfizer, website: http://www.pfizer.com/, Copyright Pfizer Inc 2024., research and development; ABRYSVO; antiviral vaccines; [...]

Telehealth Utilization Increased by over Five Percent in Three out of Four Regions; Utilization for Acute Respiratory Diseases Increased Significantly in All Regions Diabetes Mellitus Joined the Rankings of Top [...]

Guggenheim 6th Annual Biotechnology Conference Oppenheimer 34th Annual Healthcare Life Sciences Conference LANGHORNE, Pa. -- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today [...]

UTRECHT, Netherlands, Jan. 15, 2024 /PRNewswire/ --Essen University Hospital (UME) will rely on the leading digital health platform Luscii for the remote monitoring of patients with respiratory diseases. The collaboration [...]

2024 JUN 30 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Investigators publish new report on obstructive sleep apnea. According to [...]